GLP-1 Agonists Improve Outcomes in Psoriatic Arthritis with Obesity: Study
USA: A phase III randomized trial showed that adding a GLP-1 agonist to standard psoriasis treatment significantly improved outcomes in patients with psoriatic arthritis (PsA) who were overweight or obese, suggesting a beneficial adjunctive role in this population.
A new study published in Arthritis & Rheumatology by Joseph F Merola and colleagues evaluated whether combining ixekizumab (IXE), an IL-17 inhibitor, with tirzepatide (TZP), a GLP-1 receptor agonist, could offer enhanced clinical benefits compared to ixekizumab alone in adults with active PsA and excess weight.
Overweight and obesity are highly prevalent among patients with PsA, affecting up to 80% of individuals, and are known to worsen disease activity and treatment response. The TOGETHER-PsA trial, a 52-week phase 3b randomized study, enrolled adults with active PsA who had either overweight with at least one weight-related comorbidity or obesity. Participants were assigned to receive either ixekizumab in combination with tirzepatide or ixekizumab alone, using standard approved doses.
The primary endpoint was a composite measure requiring both a 50% improvement in the American College of Rheumatology criteria (ACR50) and at least a 10% reduction in body weight at 36 weeks.
The trial findings were as follows:
- Combination therapy (ixekizumab + tirzepatide) showed a clear advantage, with nearly one-third of patients achieving the primary endpoint compared to less than 1% with ixekizumab alone.
- Higher ACR50 response rates were observed in the combination therapy group.
- Clinical benefits appeared early, with noticeable separation between groups as early as week 4.
- Improvements in joint symptoms were greater with the combination approach.
- Secondary outcomes, including ACR20 responses and minimal disease activity, also favored combination therapy.
- Skin disease severity, assessed by Psoriasis Area and Severity Index, improved more with the combined treatment.
- Patient-reported outcomes indicated better physical function with combination therapy.
- Fatigue levels were reduced, as reflected in improved Functional Assessment of Chronic Illness Therapy-Fatigue scores.
- The safety profile remained consistent with known effects of both drugs, with no new safety concerns and comparable adverse event rates.
The findings suggest that targeting metabolic pathways alongside inflammation may offer a more comprehensive treatment strategy for PsA, particularly in patients with obesity or related comorbidities. By simultaneously improving disease activity, physical function, and weight, the combination of ixekizumab and tirzepatide may help reduce overall disease burden.
The authors conclude that this dual-therapy approach represents a promising advancement in the management of PsA with coexisting metabolic challenges, although further long-term studies may be needed to confirm sustained benefits and safety.
Reference:
Merola JF, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D, Kartman CE, Fischer P, Sun L, MartÃnez-Osuna P, Kronbergs A, Prajapati P, Cardoso A, Genovese MC, Ogdie A. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis Rheumatol. 2026 Mar 28. doi: 10.1002/art.70134. Epub ahead of print. PMID: 41903163.
Next Story